Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

not met at the highest dose evaluated as monotherapy (1000 mg). - No evidence of altered cardiac activity was observed. - Majority of adverse events were mild and mainly occurred during the loading doses. Adverse events consisted of chills, itching and fatigue in over a third of patients. - There was a trend for increasing incidence of some mild adverse events with escalating OGX-427 doses. For example, 33% of patients at the 200-mg dose compared to 67% of patients at the 1000-mg dose had mild adverse events during the loading doses. - The half-life of OGX-427 in the blood remained constant, although there appeared to be an increase in maximum blood levels and a corresponding decease in blood clearance of OGX-427 as doses were escalated.

The combination of 800 mg OGX-427 with docetaxel was also well tolerated and escalation to 1000 mg OGX-427 with docetaxel will be evaluated next.

Circulating Tumor Cell and Tumor Marker Results

Circulating tumor cells (CTCs), an emerging metric to assess treatment effect, was evaluated at baseline before treatment and during treatment. Both total and Hsp27-positive CTCs were evaluated. Declines of 50% or greater in both total and Hsp27-positive CTCs were observed in over half of the patients in each cohort and in each cancer category. Declines in Hsp27 CTCs to 5 or less cells occurred in 27% of patients who had greater than 5 CTCs at baseline.

Reduction in tumor markers defined as declines of PSA levels in prostate cancer or CA-125 levels in ovarian cancer were also observed. A reduction in PSA level was observed in 7 of 20 patients (35%) with prostate cancer and a reduction in CA-125 levels was observed in 3 of 5 patients (60%) with ovarian cancer.

"CTCs are emerging as an exciting surrogate of anti-cancer activity. The frequent decreases in total
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015  The Companion Diagnostics ... understanding and unprecedented access to the partnering deals ... healthcare companies during 2014. Using these ... into the partnering activities of the past year. ... the partnering and alliances deals announced worldwide.The initial ...
(Date:5/27/2015)... 27, 2015 RXi Pharmaceuticals Corporation (NASDAQ: ... discovering and developing innovative therapies primarily in the ... has commenced a public offering of shares of ... its common stock and overallotment purchase rights to ... of common stock, warrants and overallotment purchase rights ...
(Date:5/27/2015)... , May 26, 2015 ... announced the addition of Jain PharmaBiotech,s new ... and Companies" to their offering. ... molecular diagnostics technologies that will play an ... health, pharmaceutical industry, forensics and biological warfare ...
(Date:5/27/2015)... , May 26, 2015 Research and ... the "Global Breast Cancer Monoclonal Antibodies Market ... Globally, Roche seems to dominate the breast ... Its block buster molecule, Herceptin has been able ... was found that breast cancer cells become recalcitrant ...
Breaking Biology Technology:Companion Diagnostics Deals and Alliances of 2014 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 2Global Molecular Diagnostics Market 2015-2024 - Analysis of Key Technologies, Markets and Companies 3Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3
... July 26 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) will ... Thursday, August 5, 2010 at 4:30 p.m. Eastern time ... , , ... States ) or (707) 287-9361 (International). In addition, the call will be webcast ...
... and TORONTO , July 26 ... testing in clinical research and diagnostics, has acquired Xceed Molecular, ... Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip. The ... of Clinical Chemistry (AACC) annual meeting and Clinical Lab Expo, ...
... SHANGHAI , July 23 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,("China-Biotics", ... probiotics products in China , today announced,it will host a conference ... 9, 2010 to discuss the fiscal year 2011 first quarter financial ... , , ...
Cached Biology Technology:Axela Acquires Xceed Molecular Creating Powerhouse in Robust and Easy-to-Use Systems for Translational Medicine 2Axela Acquires Xceed Molecular Creating Powerhouse in Robust and Easy-to-Use Systems for Translational Medicine 3Axela Acquires Xceed Molecular Creating Powerhouse in Robust and Easy-to-Use Systems for Translational Medicine 4China-Biotics to Report Fiscal Year 2011 First Quarter Financial Results on August 9 2
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
(Date:5/26/2015)... May 26, 2015 Research ... addition of the "Saudi Arabia Biometric Systems ... their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric ... is projected to grow at over 22% ... is attributed to the surging demand for better ...
(Date:5/25/2015)... SYDNEY , May 25, 2015  Australia,s market ... inception stage, although 2014 saw the advent of several ... on 24 April 2015 is expected to ignite interest ... devices in Australia . This in ... the industry and drive new partnerships amongst vendors and ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4
... BioMed Central and Wilfrid Laurier University today announce ... that provides a visible point of open access ... the University community. Built on BioMed ... extensive open access knowledge and technology experience, Laurier ...
... the mice the researchers found alterations which may be closely ... of an international study led by the Leipzig Max Planck ... the current issue of the renowned journal Cell . ... Mnchen have generated and analyzed a mouse model in which ...
... Technology, an award-winning biometric technology research and development ... leader in workforce management solutions, has chosen M2SYS ... solution that seamlessly interfaces with Kronos time and ... fingerprint and finger vein identification, enabling Kronos customers ...
Cached Biology News:'Canadian excellence' strengthened by extensive adoption of open access 2Mouse model provides clues to human language development 2M2SYS Technology to Offer Desktop Biometric Technology to Kronos Customers 2
Glutamate Receptor 5/1a...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Dog polyclonal to Porcine Pancreatic Islets of Langerhans Cells ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Pig): Sonicated crude membrane fraction of porcine p...
Biology Products: